title: DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival.
abstract: Breast cancer patients with Luminal A disease generally have a good prognosis, but among this patient group are patients with good prognosis that are currently overtreated with adjuvant chemotherapy, and also patients that have a bad prognosis and should be given more aggressive treatment. There is no available method for subclassification of this patient group. Here we present a DNA methylation signature (SAM40) that segregates Luminal A patients based on prognosis, and identify one good prognosis group and one bad prognosis group. The prognostic impact of SAM40 was validated in four independent patient cohorts. Being able to subdivide the Luminal A patients may give the two-sided benefit of identifying one subgroup that may benefit from a more aggressive treatment than what is given today, and importantly, identifying a subgroup that may benefit from less treatment.
authors.affiliation: Department of Cancer Genetics, Institute for Cancer Research, OUS Radiumhospitalet, Oslo, Norway.
authors.forename: Thomas
authors.initials: T
authors.lastname: Fleischer
authors.affiliation: Department of Cancer Genetics, Institute for Cancer Research, OUS Radiumhospitalet, Oslo, Norway.|Department of Clinical Molecular Biology and Laboratory Science (EpiGen), Akershus University hospital, Division of Medicine, Lørenskog, Norway.
authors.forename: Jovana
authors.initials: J
authors.lastname: Klajic
authors.affiliation: Department of Cancer Genetics, Institute for Cancer Research, OUS Radiumhospitalet, Oslo, Norway.
authors.forename: Miriam Ragle
authors.initials: MR
authors.lastname: Aure
authors.affiliation: Systems Biology Laboratory, Institute of Biomedicine and Genome-Scale Biology Research Program, University of Helsinki, Finland.
authors.forename: Riku
authors.initials: R
authors.lastname: Louhimo
authors.affiliation: Department of Cancer Genetics, Institute for Cancer Research, OUS Radiumhospitalet, Oslo, Norway.
authors.forename: Arne V
authors.initials: AV
authors.lastname: Pladsen
authors.affiliation: Department of Cancer Genetics, Institute for Cancer Research, OUS Radiumhospitalet, Oslo, Norway.
authors.forename: Lars
authors.initials: L
authors.lastname: Ottestad
authors.affiliation: Laboratory for Epigenetics and Environment, Centre National de Génotypage, CEA - Institut de Génomique, France.
authors.forename: Nizar
authors.initials: N
authors.lastname: Touleimat
authors.affiliation: Systems Biology Laboratory, Institute of Biomedicine and Genome-Scale Biology Research Program, University of Helsinki, Finland.
authors.forename: Marko
authors.initials: M
authors.lastname: Laakso
authors.affiliation: Department of Cancer Genetics, Institute for Cancer Research, OUS Radiumhospitalet, Oslo, Norway.
authors.forename: Ann Rita
authors.initials: AR
authors.lastname: Halvorsen
authors.affiliation: Department of Cancer Genetics, Institute for Cancer Research, OUS Radiumhospitalet, Oslo, Norway.
authors.forename: Grethe I
authors.initials: GI
authors.lastname: Grenaker Alnæs
authors.affiliation: Department of Clinical Molecular Biology and Laboratory Science (EpiGen), Akershus University Hospital, Division of Medicine, Lørenskog, Norway.|Department of Surgery, Akershus University Hospital, Lørenskog, Norway.|Deptartment of Breast and Endocrine Surgery, Oslo University Hospital, Ullevål, Norway.
authors.forename: Margit L H
authors.initials: ML
authors.lastname: Riis
authors.affiliation: Department of Cancer Genetics, Institute for Cancer Research, OUS Radiumhospitalet, Oslo, Norway.|Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.
authors.forename: Åslaug
authors.initials: Å
authors.lastname: Helland
authors.affiliation: Systems Biology Laboratory, Institute of Biomedicine and Genome-Scale Biology Research Program, University of Helsinki, Finland.
authors.forename: Sampsa
authors.initials: S
authors.lastname: Hautaniemi
authors.affiliation: Section of Oncology, Institute of Clinical Science, University of Bergen, Bergen, Norway.|Department of Oncology, Haukeland University Hospital, Bergen, Norway.
authors.forename: Per Eystein
authors.initials: PE
authors.lastname: Lønning
authors.affiliation: Cancer Clinic, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
authors.forename: Bjørn
authors.initials: B
authors.lastname: Naume
authors.affiliation: Department of Cancer Genetics, Institute for Cancer Research, OUS Radiumhospitalet, Oslo, Norway.
authors.forename: Anne-Lise
authors.initials: AL
authors.lastname: Børresen-Dale
authors.affiliation: Laboratory for Epigenetics and Environment, Centre National de Génotypage, CEA - Institut de Génomique, France.
authors.forename: Jörg
authors.initials: J
authors.lastname: Tost
authors.affiliation: Department of Cancer Genetics, Institute for Cancer Research, OUS Radiumhospitalet, Oslo, Norway.|Department of Clinical Molecular Biology and Laboratory Science (EpiGen), Akershus University hospital, Division of Medicine, Lørenskog, Norway.
authors.forename: Vessela N
authors.initials: VN
authors.lastname: Kristensen
mesh_terms: D014408:Biomarkers, Tumor; D001943:Breast Neoplasms / Q000235:genetics* / Q000401:mortality* / Q000473:pathology; D016000:Cluster Analysis; D019175:DNA Methylation; D044127:Epigenesis, Genetic; D057890:Epigenomics / Q000379:methods; D005260:Female; D018628:Gene Dosage; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D053208:Kaplan-Meier Estimate; D011379:Prognosis; D059467:Transcriptome
chemical_list: D014408:Biomarkers, Tumor
keywords: DNA methylation; Luminal A; breast cancer; classification; prognosis